Allogenic Bone-Marrow-Derived Mesenchymal Stem Cells: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Allogenic Bone-Marrow-Derived Mesenchymal Stem Cells. Educational only — not medical advice.
Labeled uses
RYONCIL is indicated for the treatment of steroid refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older.
Source: FDA labeling via NIH DailyMed (set a4e0918f…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.